## Core Concept
Thalassemias are a group of genetic disorders affecting hemoglobin synthesis, characterized by reduced or absent production of one or more globin chains. β-thalassemia major, also known as Cooley's anemia, results from mutations that significantly reduce or eliminate β-globin chain production. This leads to a relative excess of α-globin chains, causing erythrocyte damage and ineffective erythropoiesis.

## Why the Correct Answer is Right
The correct management for β-thalassemia major often involves regular blood transfusions to maintain adequate hemoglobin levels and reduce erythropoietic drive. Chelation therapy is also crucial to manage iron overload resulting from frequent transfusions. Among the provided options, **iron chelation therapy** is a cornerstone in the management of β-thalassemia major to prevent complications associated with iron overload, such as cardiac and hepatic dysfunction.

## Why Each Wrong Option is Incorrect
- **Option A:** While monitoring and management of complications are part of care, they are not specific treatments like iron chelation.
- **Option B:** Although hydroxyurea may be used in some cases of thalassemia to increase fetal hemoglobin production, it is not the primary treatment for β-thalassemia major.
- **Option C:** This option might relate to supportive care but does not directly address the primary issue of iron overload.

## Clinical Pearl / High-Yield Fact
A key clinical pearl in managing β-thalassemia major is the importance of **iron chelation therapy** to prevent iron overload, which can lead to organ failure. Chelating agents like deferoxamine, deferiprone, or deferasirox help mitigate this risk. Regular monitoring of iron levels and adjustment of chelation therapy are critical.

## Correct Answer Line
**Correct Answer: D.**